Artificial Intelligence is making significant strides in the field of biopharmaceuticals, particularly with the advancements seen in Google DeepMind's deep learning model, which predicts complex protein structures--key components in virtually every biological process.
As AI continues to generate an increasing number of potential drug candidates, a new challenge has emerged: effectively characterizing these candidates for testing and eventual production. Addressing this challenge is the mission of 10x Science, a startup founded in December 2025 that recently secured $4.8 million in seed funding, led by Initialized Capital, with contributions from Y Combinator, Civilization Ventures, and Founder Factor.
The founding team, which includes experienced biochemists David Roberts and Andrew Reiter, alongside AI expert Vishnu Tejas, aims to streamline the drug development process. "While biopharma utilizes various predictive tools to identify drug candidates, all of them must undergo thorough characterization," Roberts explained. "Measurement is essential at every stage."
Understanding protein structures is crucial for developing biologic drugs, which are designed to target specific diseases. A prime example is Keytruda, a drug by Merck that enhances the immune system's ability to combat cancer.
The trio of founders previously collaborated in the Stanford lab of Nobel laureate Dr. Carolyn Bertozzi, where they explored cancer cell interactions and encountered frustrations due to the complexities of molecular understanding.
10x Science employs a sophisticated method known as mass spectrometry to assess molecular structures. This technique, while accurate, generates intricate data that requires expert analysis, often consuming considerable time.
10x's platform integrates deterministic algorithms with AI agents capable of interpreting spectrometry data. This innovation aims to provide a traceable analysis process, essential for regulatory compliance in drug development.
Matthew Crawford, a scientist at Rilas Technologies, has been utilizing the 10x Science platform and reports significant improvements in efficiency. He noted that the AI's ability to autonomously gather relevant data and adapt to different molecular evaluations sets it apart from other tools he has used.
"For instance, when I tested a specific protein, the platform accurately identified it based on the file name and searched online databases for its sequence, eliminating the need for manual input," Crawford shared.
10x Science is also collaborating with several major pharmaceutical companies and academic institutions. The founders plan to use the seed funding to expand their team and refine their model, aiming to redefine molecular intelligence by integrating protein structures with cellular data.
As the founders envision, the platform could transform the drug development landscape, providing a valuable resource for researchers who may lack the time or expertise to navigate complex molecular techniques.
In essence, 10x Science represents a promising advancement in biopharma, potentially reshaping how drug candidates are identified and characterized, thus paving the way for more efficient and effective therapeutic solutions in the future.